Eyenovia, Inc.

Blink, and it’s gone! It’s been just over a week since the American Academy of Ophthalmology, and Eyenovia extends its sincere thanks to the ophthalmic leaders who attended our AAO 2024 Advisory Board in Chicago. The thoughtful and engaging discussions surrounding our products were invaluable, providing key insights that will help propel the momentum behind our commercial launches of Clobetasol and MydCombi even further. We are excited to incorporate these perspectives as we continue to advance our portfolio. Thank you once again to our esteemed advisors for an evening of productive discussion and shared learning! Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com Interested in more information and how to get MydCombi? mydcombi.com   Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca    #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare #AAO2024

The latest addition to the Socialite Vision family Eyenovia, Inc. thanks Paul S. Mike Ruiz

Thank you, Francis Mah, MD, for being among the early adopters of Clobetasol, the next-generation ophthalmic steroid! We are pleased to see that you are actively prescribing Clobetasol for your patients. Renowned for his contributions as an ophthalmologist and respected researcher, speaker, and thought leader, Dr. Mah is dedicated to enhancing patient outcomes through innovative treatment approaches. Clobetasol empowers him to deliver powerful, swift relief from post-surgical pain and inflammation. With twice-a-day dosing, this state-of-the-art treatment has the potential to deliver quicker recovery times and improved overall patient experience. Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com/ Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare   INDICATIONS AND USAGE: Clobetasol Propionate Ophthalmic Suspension 0.05% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. CONTRAINDICATIONS: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Full Prescribing Information: https://lnkd.in/gWYjgSiN

Dagny Zhu, M.D., the Medical Director and Partner of NVISION Eye Centers Rowland Heights, was one of the first in the US to implement Clobetasol into her practice and post-operative patient care. She stated, "I’m excited for the ease of twice-a-day dosing for our patients. I also look forward to using Clobetasol to treat postop inflammation in our surgical patients with greater peace of mind as the data suggests a low risk of IOP spikes."    As a key opinion leader in advanced cataract surgery and LASIK surgery, Dr. Zhu has been featured in over 200 lectures, presentations, publications, and press features. We are thrilled to have an expert like herself using Clobetasol!   Learn more about NVISION and Dr. Zhu: https://lnkd.in/gJ5rfZbQ Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com/ Learn how Eyenovia is making it possible by visiting: https://bit.ly/3oEM9Ca #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare   INDICATIONS AND USAGE: Clobetasol Propionate Ophthalmic Suspension 0.05% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. CONTRAINDICATIONS: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Full Prescribing Information: https://lnkd.in/gWYjgSiN

I’m proud to be the first in Florida to partner with Eyenovia to offer the next generation in ophthalmic steroid drops. This has the potential to revolutionize post operative inflammation and optimize healing for our patients. Check out the science behind Clobetasol Propionate for you eye nerds 🤓Congrats Eyenovia! 👏 Photo used with my wonderful patient’s permission. Here’s to innovation in surgical postoperative management! Its twice-a-day indication is great 🙌 Paul S. Mike Ruiz #surgery #ophthalmology Eyenovia, Inc. #eyehealth #glaucoma #cataract #gaass #SLT Ehsan Sadri MD FACS

Thank you to Eyewire+ News for highlighting the US launch of Clobetasol! We are thrilled to see the positive reception of this innovative treatment, and we appreciate the support from Eyewire in sharing this milestone. We envision Clobetasol as a game-changer for post-operative outcomes and are proud to introduce this next-generation steroid to the eye care market.    Check out the full video here: https://lnkd.in/gdMHmsbP Interested in more information and how to get Clobetasol Propionate? clobetasolbid.com/ Learn how Eyenovia is making it possible by visiting: https://bit.ly/3Dik87F #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare   Contraindications: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.   See Full Prescribing Information Here: https://lnkd.in/gWYjgSiN

AND WE'RE OFF! Clobetasol is now available to eye care physicians across the US. We are excited to offer the next generation ophthalmic steroid which is designed to be easy for prescribers and their patients. Go to ClobetasolBID.com to learn more about the product and for ordering information. To read our latest press release: https://lnkd.in/gZFNKqry #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare Contraindications: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. See Full Prescribing Information Here: https://lnkd.in/gWYjgSiN

Big thanks to Glance by Eyes on Eyecare for the comprehensive coverage of Clobetasol and their deep-dive into its revolutionary potential in eye care. We are excited to offer a new standard of care for patients and transform the landscape of post-operative ophthalmic pain and inflammation with Clobetasol. Check out the full article for all the details on this exciting development!   LINK: https://lnkd.in/gFWMyjwM   #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare   Contraindications: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.   See Full Prescribing Information Here: https://lnkd.in/gWYjgSiN

THIS IS A BIG DEAL – Clobetasol has arrived! The future of post-surgical pain and inflammation management has officially landed in the US. The official launch begins shortly! Stay tuned for more updates. #ophthalmology #optometry #launch #pharmaceuticals #innovation #eyenovia #formosa #ocularsurgery #ASCRS #eyecare Contraindications: Clobetasol Propionate Ophthalmic Suspension 0.05% is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. See Full Prescribing Information Here: https://lnkd.in/gWYjgSiN

Formosa Pharmaceuticals, Inc., is excited to announce the successful shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to Eyenovia, Inc. in the United States for Commercialization. This achievement signals a major advancement in delivering innovative ophthalmic therapies to the market for both Formosa Pharmaceuticals, Inc. and Bora Pharmaceuticals. https://shorturl.at/zxkLy 🚛 🛫 🚀 #ClobetasolPropionate #FirstShipment #Commercialization #ClobetasolBID